GenomeUp

Based in Rome, Italy, GenomeUp develops an AI-powered Software as a Medical Device platform that supports genetic analysis and clinical decision-making for diagnosing rare diseases and early-stage cancer conditions. The company's core product, JuliaOmix, integrates genomics and microbiome data to provide actionable diagnostic insights for hospitals, genetic laboratories, research centers, and pharmaceutical companies in under 24 hours. Operating under a business-to-business software-as-a-service licensing model, the platform has securely processed 2 petabytes of genetic data across approximately 45,000 patients and completed over 18,000 distinct sequencing processes. The enterprise has raised $8.42 million in total equity funding, including a recent $4.95 million growth round to support international expansion, backed by venture capital investors including Lumen Ventures, LVenture Group, The Techshop, and Zest Group. GenomeUp was originally founded in 2017 by executive co-founders Simone Gardini and Giovanni Stracquadaneo.